Tomsche David Scott 4

What Happened David Scott Tomsche, a director of Immucell Corp. (ICCC), received a grant/award of derivative securities covering 11,933 shares on April 15, 2026. The filing reports an acquisition at $0.00 (derivative grant)—the instrument is described in a footnote as stock options that vest over three years. This was a compensation grant to a board member, not an open-market purchase or sale, so there was no immediate cash paid or shares sold.

Key Details

• Transaction date: 2026-04-15; filing date: 2026-04-16 (timely).
• Transaction type/code: Grant/Award (derivative) — reported price $0.00.
• Shares involved: 11,933 underlying shares.
• Vesting (footnote): 3,977 shares become exercisable on each of Apr 15, 2027 and Apr 15, 2028; 3,979 shares exercisable on Apr 15, 2029.
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Remarks in filing: Options were granted by the issuer to compensate directors for board service.

Context This was a time‑vesting option award for director compensation, not an exercised option or a stock sale — no immediate market transaction or proceeds. Such grants are common to align directors’ incentives with shareholders but do not necessarily signal buying or selling intent. The filing reports an exercise/acquisition price of $0.00 and describes the award as stock options; consult future filings or company disclosures for details on exercise price mechanics or grant agreements.